Cannabinoid Safety in Adults Over 50: Meta-Analysis Review
This meta-analysis highlights cannabinoid safety older adults, showing low adverse event rates for THC and CBD alone. Combination THC:CBD products showed higher withdrawal rates. The study emphasizes cautious use and the need for controlled trials in…
Cannabis Medicines Cause Dose-Dependent Side Effects in Older Adults, Meta-Analysis Finds
Dose-dependent side effects cannabinoids cause include dizziness, dry mouth, and coordination difficulties in older adults. This 2024 meta-analysis highlights the importance of cautious dosing. Understanding these risks helps clinicians manage…
Prevalence of Schizophrenia Spectrum and Bipolar Disorder Among Cannabis Induced Psychosis Patients
Cannabis induced psychosis risk is a critical clinical concern with significant implications for patient prognosis. This review provides prevalence data on progression to schizophrenia spectrum and bipolar disorder. Understanding this risk helps guide…
Therapeutic Use of Cannabis and Cannabinoids: A Comprehensive Review
This review covers therapeutic cannabinoid applications with a focus on FDA-approved uses. It highlights evidence supporting cannabinoids for nausea, appetite, and seizure disorders. Approximately 27% of adults report medical cannabis use, underscoring…
Impact of Preoperative Cannabis Use on Spinal Fusion Outcomes
This systematic review examines preoperative cannabis use spinal fusion and its impact on perioperative outcomes. Cannabis users undergoing spinal fusion require more opioids and face higher readmission and reoperation rates. Understanding these effects…
Maternal Cannabis & Autism/ADHD Risk: Clinical Evidence
Maternal cannabis use in pregnancy risks research indicates a modestly elevated risk for autism spectrum disorder and ADHD in children. Cannabis compounds cross the placental barrier and may affect fetal brain development. These findings support caution…
Cannabis-based medicines for chronic neuropathic pain in adults.
Estimates of chronic neuropathic pain affect 6% to 10% of adults. Cannabis-based medicines for chronic neuropathic pain offer a potential treatment option when conventional therapies fail. Current evidence suggests modest benefits with important safety…
CBD Probably Reduces Seizures in Refractory Epilepsy, But Raises Risk of Serious Adverse Events
Cannabidiol treatment resistant epilepsy shows probable seizure reduction benefits at 10 and 20 mg/kg/day doses. However, cannabidiol treatment resistant epilepsy also raises the risk of serious adverse events. This systematic review highlights the need…
Comprehensive Guide to Endocannabinoid System Clinical Research
This endocannabinoid system clinical research guide highlights genetic variants linked to psychiatric disorders. The study identifies key SNPs in the DAGLA gene associated with mental health risks. Understanding these findings aids in contextualizing the…
Cannabidiol Probably Reduces Seizures in Drug-Resistant Epilepsy—But Serious Side Effects Also Rise
The cannabidiol pediatric epilepsy dosing 2025 review shows that pharmaceutical-grade cannabidiol probably reduces seizures in treatment-resistant epilepsy. This review highlights a meaningful benefit-risk trade-off with increased serious adverse events…